Investegate |Formycon AG Announcements | Formycon AG: Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
Investegate announcements from Formycon AG, Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
United States Polpharma Biologics Group Corporate Communications Coherus Biosciences Inc Drug Administration Genentech Inc
Source: investegate.co.uk